Literature DB >> 14688584

The march toward rational therapeutics in children.

Richard L Gorman1.   

Abstract

Although children suffer from many of the same diseases as adults, the majority of drugs are not approved for pediatric use. This places children at risk, either that they will not be treated adequately because of the lack of approved agents or that their physician will be lacking the necessary labeling information to treat appropriately with a given agent. This paper details the slow progress over the last 25 years toward providing pediatric labeling and thus providing children with optimal protection and range of treatment options.

Entities:  

Mesh:

Year:  2003        PMID: 14688584     DOI: 10.1097/01.inf.0000101846.83256.5a

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  2 in total

1.  Ethical principles and legal requirements for pediatric research in the EU: an analysis of the European normative and legal framework surrounding pediatric clinical trials.

Authors:  Wim Pinxten; Kris Dierickx; Herman Nys
Journal:  Eur J Pediatr       Date:  2009-01-14       Impact factor: 3.183

2.  The Need for Pediatric Drug Development.

Authors:  Robert M Ward; Daniel K Benjamin; Jonathan M Davis; Richard L Gorman; Ralph Kauffman; Gregory L Kearns; Mary Dianne Murphy; Catherine M T Sherwin
Journal:  J Pediatr       Date:  2017-09-21       Impact factor: 4.406

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.